Morepen Laboratories has developed and added three new drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in domestic and global markets. The three bulk drugs / APIs are Rivaroxaban (trade name-Xarelto), Vildagliptin (trade names- Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid). While two products Rivaroxaban and Yildagliptin will augment the company’s presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment.
Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.
